Atypical Ductal Breast Hyperplasia
NCI Definition: A neoplastic process that arises from the terminal ductal lobular unit of the breast parenchyma. It is usually solitary and confined to a single lobular unit. It is characterized by the presence of a monomorphic epithelial proliferation in a cribriform, micropapillary, or solid growth pattern. Focal architectural features of low grade ductal carcinoma in situ are present. There is an increased risk for development of invasive breast carcinoma. 
There is 1 clinical trial for atypical ductal breast hyperplasia, of which 1 is open and 0 are completed or closed. Of the trial that contains atypical ductal breast hyperplasia as an inclusion criterion, 1 is phase 2 (1 open).
Placebo and ruxolitinib are the most common interventions in atypical ductal breast hyperplasia clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.